CLINICAL_TRIALS ClinicalTrials.gov record update

Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02830594
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:57.572734+00:00
Published At: 2022-06-30T00:00:00+00:00
Record Updated At: 2024-02-20
Results Posted At: 2022-06-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Gastric Adenocarcinoma", "Gastric Squamous Cell Carcinoma", "Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Neoplasm in the Stomach", "Stage IV Esophageal Adenocarcinoma AJCC v7", "Stage IV Esophageal Squamous Cell Carcinoma AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-02-20"
protocolSection.identificationModule.nctId: "NCT02830594"
protocolSection.identificationModule.officialTitle: "Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-06-30"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.